Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 4.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 505,289 shares of the biotechnology company’s stock after purchasing an additional 22,225 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Exelixis were worth $16,826,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Seizert Capital Partners LLC increased its stake in Exelixis by 8.0% in the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after purchasing an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after acquiring an additional 991,494 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Exelixis by 60.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after acquiring an additional 20,641 shares during the last quarter. Tri Ri Asset Management Corp acquired a new stake in Exelixis during the third quarter worth about $4,396,000. Finally, CWA Asset Management Group LLC acquired a new stake in Exelixis during the third quarter worth about $577,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EXEL has been the subject of several research analyst reports. The Goldman Sachs Group upgraded Exelixis to a “strong sell” rating in a research note on Tuesday, October 15th. Stephens restated an “equal weight” rating and set a $29.00 price target on shares of Exelixis in a research note on Monday, January 27th. Piper Sandler upped their price target on Exelixis from $36.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, January 13th. Brookline Capital Management initiated coverage on Exelixis in a research report on Monday, December 23rd. They issued a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Exelixis in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.06.

Insider Transactions at Exelixis

In related news, EVP Dana Aftab sold 96,986 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $35.00, for a total value of $3,394,510.00. Following the sale, the executive vice president now owns 498,945 shares of the company’s stock, valued at approximately $17,463,075. This trade represents a 16.27 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Patrick J. Haley sold 41,588 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $34.36, for a total value of $1,428,963.68. Following the completion of the sale, the executive vice president now directly owns 288,665 shares in the company, valued at approximately $9,918,529.40. This trade represents a 12.59 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 208,574 shares of company stock worth $7,376,374. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Trading Up 0.7 %

Shares of EXEL opened at $33.15 on Friday. The firm has a market cap of $9.47 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 0.72 and a beta of 0.53. The stock has a 50 day moving average of $34.68 and a 200-day moving average of $30.08. Exelixis, Inc. has a 52 week low of $20.01 and a 52 week high of $37.59.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04. The company had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. On average, sell-side analysts predict that Exelixis, Inc. will post 1.74 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.